Subanesthetic ketamine alters EEG signal complexity: Implications for treatment stratification in depression.
Journal of Affective Disorders October 1, 2025 Weng-Lam Chan, Sebastian Olbrich, Xinwen Jiang et al. 3 citations
Major depressive disorder, particularly its treatment-resistant form (TRD), poses significant treatment challenges. Ketamine, an N-methyl-d-aspartate receptor antagonist, has shown promise in rapidly alleviating depressive symptoms by influencing neuroplasticity and glutamatergic modulation, which are thought to influence brain activity complexity. In this placebo-controlled study, we examined...